Nkarta Reports Q3 2025 Financial Results: Cumulative Net Loss of $76.68 Million, EPS Beat Expectations
Nkarta (NKTX) reported Q3 2025 financial results on November 10, 2025.
Cumulative net loss for the first three quarters of 2025 was $76.68 million, a 7.46% improvement from $82.86 million year-over-year.
Q3 2025 EPS was -$0.29, beating analyst estimates of -$0.31 by 6.45%.
Q3 2025 operating expenses totaled $23.43 million, with net income of -$21.72 million.
Nkarta is a clinical-stage biopharmaceutical company developing allogeneic NK cell therapies for autoimmune diseases and hematologic malignancies.